Coadministration of Rifampin Significantly Reduces Odanacatib Concentrations in Healthy Subjects

This open‐label 2‐period study assessed the effect of multiple‐dose administration of rifampin, a strong cytochrome P450 3A (CYP3A) and P‐glycoprotein inducer, on the pharmacokinetics of odanacatib, a cathepsin K inhibitor. In period 1, 12 healthy male subjects (mean age, 30 years) received a single...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical pharmacology 2017-01, Vol.57 (1), p.110-117
Hauptverfasser:	Stoch, S. Aubrey, Ballard, Jeanine, Gibson, Christopher, Kesisoglou, Filippos, Witter, Rose, Kassahun, Kelem, Zajic, Stefan, Mehta, Anish, Brandquist, Christine, Dempsey, Cynthia, Stypinski, Daria, Reitman, Marc L.
Format:	Artikel
Sprache:	eng
Schlagworte:	4β‐hydroxycholesterol ADME Adult ATP-Binding Cassette, Sub-Family B, Member 1 - blood Biphenyl Compounds - administration & dosage Biphenyl Compounds - blood CYP3A4 Cytochrome P-450 CYP3A Inducers - administration & dosage Drug Administration Schedule Drug Interactions - physiology Healthy Volunteers Humans Male Middle Aged odanacatib P‐glycoprotein rifampin Rifampin - administration & dosage Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!